Regulation of the D1 dopamine receptor through cAMP-mediated pathways.
Sibley
D R
DR
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
Ventura
A L
AL
Jiang
D
D
Mak
C
C
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004298:Dopamine / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D005910:Glioma; D007700:Kinetics; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000096:biosynthesis; D015398:Signal Transduction; D013873:Thionucleotides / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured
D001552:Benzazepines; D017447:Receptors, Dopamine D1; D011994:Recombinant Proteins; D013873:Thionucleotides; D015124:8-Bromo Cyclic Adenosine Monophosphate; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D004298:Dopamine